ConductScience.org, home

Comparison · NCT03271021-a7bfef96

FMX101, 4% Minocycline Foam vs Vehicle Foam: IGA Treatment Success (Dichotomized as Yes/no) at Week 9, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 9

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. FMX101, 4% Minocycline Foam vs Vehicle Foam: IGA Treatment Success (Dichotomized as Yes/no) at Week 9, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 9. Trial comparisons, record NCT03271021-a7bfef96. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03271021-a7bfef96

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1860.1590.215wilson
Risk in group 20.1050.08530.129wilson
Risk difference, group 1 minus group 20.08030.04460.116newcombe hybrid score
Risk ratio, group 1 over group 21.761.362.28log
Odds ratio, group 1 over group 21.941.442.61log
Number needed to treat, for one more participant with the outcome on FMX101, 4% Minocycline Foam than on Vehicle Foam12.58.6222.4from the risk difference interval

Groups2

Group 2 names the comparator: vehicle.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1FMX101, 4% Minocycline FoamFMX101, 4% minocycline foam applied topically once daily for 12 weeks~FMX101: FMX101, 4% minocycline foam137738OG000
Group 2Vehicle FoamVehicle foam applied topically once daily for 12 weeks~Vehicle Foam: Vehicle Foam79750OG001

Outcome

Type
SECONDARY
Title
IGA Treatment Success (Dichotomized as Yes/no) at Week 9, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 9
Description
Time frame
9 weeks
Population

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris
NCT number
NCT03271021
Phases
PHASE3
Conditions
Acne Vulgaris
Interventions
FMX101, Vehicle Foam
Lead sponsor
Vyne Therapeutics Inc.
Results first posted
2020-02-21

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03271021-a7bfef96